OsteoCure Therapeutics
Accelerating Bone Repair While Reducing Pain
Team
Hunter Newman, PhD
Co-founder and CEO
Shyni Varghese, PhD
Co-founder and CTO
Ken Gall, PhD
Board Member
Samuel Adams, MD
Clinical Advisor
Technology
OsteoCure Therapeutics is a Duke University spinout focused on accelerating bone repair while reducing pain. Our multifunctional, injectable system is cost-effective and easy for surgeons to integrate into their practice. Our working prototype demonstrates the potential to bolster bone repair in healthy and impaired healing animal models, while also reducing animal pain. Our product can be used for many bone applications spanning a $25B market.
Publications
In Vivo Sequestration of Innate Small Molecules to Promote Bone Healing
Bone patch containing bornic acid demonstrated biomaterial assisted sequestration of small molecules to localize pro-regenerative signaling at the injury site and accelerate bone repair.
Microgel-Assisted Delivery of Adenosine to Accelerate Fracture Healing
Application of the in situ curing scaffolds containing adenosine-loaded microgels following tibial fracture injury showed improved bone tissue healing in a mouse model.
Multi-Functional Small Molecule Alleviates Fracture Pain and Promotes Bone Healing
Demonstrates the dual role of adenosine and its material-assisted local delivery as a feasible therapeutic approach to treat bone trauma and associated pain.
Calcium Phosphate-Bearing Matrices Induce Osteogenic Differentiation of Stem Cells through adenosine signaling
Extracellular phosphate uptake through solute carrier SLC20a1 supports osteogenic differentiation of human mesenchymal stem cells via adenosine.
Extracellular adenosine signaling in bone health and disease
Purinergic signaling is a key molecular pathway in the maintenance of bone health and regeneration. P1 receptor signaling, which is activated by extracellular adenosine, has emerged as a key metabolic pathway that regulates bone tissue formation, function, and homeostasis
Small molecule–driven direct conversion of human pluripotent stem cells into functional osteoblasts
Direct conversion of hPSCs into functional osteoblasts through the use of adenosine. The hPSCs treated with adenosine not only expressed the molecular signatures of osteoblasts but also produced calcified bone matrix.
Address
701 W Main St Durham, NC 27701
Phone Number
973-600-1842
Mailing Address
hnewman@osteocuretx.com